Krystal Biotech (NASDAQ: KRYS) CEO reports new equity awards and tax share surrenders

robot
Abstract generation in progress

Krystal Biotech’s CEO, Krish S. Krishnan, reported the vesting of restricted and performance stock units, which converted into common shares. He also received new equity awards, including stock options for 45,249 shares and 18,140 restricted stock units, both vesting over four years. Notably, shares were surrendered to the company for tax withholding purposes rather than being sold on the open market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin